Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models
Dexamethasone/selinexor/triamcinolone interaction
Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
Polymorphs of Selinexor
Lenalidomide/Selinexor
BIOMARKERS FOR SELINEXOR
Selinexor/venetoclax
Decitabine/Selinexor
